Knight Cancer Institute

Medicine & Life Sciences

1. Neoplasms 100%
2. Prostatic Neoplasms 86%
3. Imatinib Mesylate 86%
4. Therapeutics 63%
5. Mutation 61%
6. Gastrointestinal Stromal Tumors 58%
7. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 56%
8. Survival 55%
9. Phosphotransferases 43%
10. Protein-Tyrosine Kinases 42%
11. Castration 42%
12. Acute Myeloid Leukemia 40%
13. Drug Therapy 40%
14. Cell Transplantation 39%
15. Transplants 39%
16. Leukemia 35%
17. Breast Neoplasms 31%
18. Genes 30%
19. Clinical Trials 29%
20. Bone Marrow 29%
21. Progression-Free Survival 28%
22. Allogeneic Cells 27%
23. Docetaxel 25%
24. Androgens 25%
25. Proteins 25%
26. MDV 3100 24%
27. Recurrence 24%
28. Safety 24%
29. Stem Cells 23%
30. Graft vs Host Disease 22%
31. Multiple Myeloma 20%
32. B-Cell Chronic Lymphocytic Leukemia 20%
33. Pharmaceutical Preparations 19%
34. Colorectal Neoplasms 19%
35. Phosphorylation 18%
36. Prostate-Specific Antigen 18%
37. Confidence Intervals 18%
38. Placebos 17%
39. Hematopoietic Stem Cells 17%
40. Biomarkers 17%
41. Cell Line 17%
42. Precursor Cell Lymphoblastic Leukemia-Lymphoma 16%
43. T-Lymphocytes 16%
44. Tissue Donors 16%
45. Transplantation 16%
46. Growth 16%
47. Unrelated Donors 16%
48. Stem Cell Transplantation 16%
49. Homologous Transplantation 16%
50. Mortality 15%
51. Neoplasm Metastasis 15%
52. Hematologic Neoplasms 15%
53. Apoptosis 15%
54. Hemorrhage 14%
55. Hematopoietic Stem Cell Transplantation 14%
56. Tyrosine 14%
57. Dasatinib 14%
58. In Vitro Techniques 13%
59. Adenocarcinoma 13%
60. Radiotherapy 13%
61. Population 13%
62. Gene Expression 13%
63. Myeloid Cells 13%
64. Cytogenetics 13%
65. Fanconi Anemia 13%
66. Non-Hodgkin's Lymphoma 13%
67. Thrombosis 13%
68. Randomized Controlled Trials 13%
69. Genome 13%
70. Renal Cell Carcinoma 12%
71. Sarcoma 12%
72. Carcinoma 12%
73. Calcium-Calmodulin-Dependent Protein Kinase Type 2 12%
74. Prostate 12%
75. Leukemia, Myeloid, Chronic Phase 12%
76. Calcitriol 11%
77. Melanoma 11%
78. Androgen Receptors 11%
79. Lymphoma, Large B-Cell, Diffuse 11%
80. Young Adult 11%
81. Philadelphia Chromosome 11%
82. pembrolizumab 10%
83. DNA 10%
84. Receptor Protein-Tyrosine Kinases 10%
85. Biopsy 10%
86. Cyclophosphamide 10%
87. MicroRNAs 10%
88. Transcriptome 10%
89. B-Lymphocytes 10%
90. Thrombocytopenia 10%
91. src Homology Domains 10%
92. Exons 9%
93. Ovarian Neoplasms 9%
94. Liver 9%
95. Sunitinib 9%
96. Radiation 9%
97. Lymphoma 9%
98. Quality of Life 9%
99. Mantle-Cell Lymphoma 9%